异甘草酸镁对恶性肿瘤化疗患者的护肝作用的临床分析
|
摘要
目的观察分析恶性肿瘤化疗患者采用异甘草酸镁治疗的护肝作用。方法便利选取该院2014年7月—2018年7月期间收治的102例恶性肿瘤化疗患者,按照不同治疗方式随机分为实验组(51例,采用异甘草酸镁治疗)和对照组(51例,采用硫普罗宁治疗),对比两组患者治疗前后血清碱性磷酸酶(ALP)、血清天门冬氨酸氨基转移酶(AST)、血清总胆红素(TBIL)、血清丙氨酸氨基转移酶(ALT)等指标变化以及不良反应发生率。结果两组患者治疗后ALP、TBIL、ALT等指标水平均高于治疗前(t=13.232,5.348,9.764,P<0.05),AST低于治疗前(t=7.354,P<0.05),但实验组患者治疗后上述各项肝功能指标改善情况均优于对照组(t=11.893,4.885,8.432,6.986,P<0.05)。实验组患者心悸、皮肤瘙痒、眼睑浮肿、过敏反应、皮肤潮红等不良反应发生率3.9%明显低于对照组29.4%(χ2=7.803,P<0.05)。结论异甘草酸镁对恶性肿瘤化疗患者具有良好的保肝作用,且不良反应发生率较低,可在临床广泛推广应用。
Objective To observe the liver protection effect of patients with chemotherapy for malignant tumors treated with magnesium isoglycyrrhizinate. Methods 102 patients with chemotherapy for malignant tumor admitted to our hospital from July 2014 to July 2018 were convenient randomly divided into experimental group(51 cases treated with magnesium isoglycyrrhizinate) and control group(51 cases with thiopro tablets treatment), compared with two groups of patients before and after treatment serum alkaline phosphatase(ALP), serum aspartate aminotransferase(AST), serum total bilirubin(TBIL), serum alanine aminotransferase(ALT) changes in indicators and the incidence of adverse reactions. Results The levels of ALP,TBIL and ALT in the two groups were higher than those before treatment(t=13.232, 5.348, 9.764, P<0.05), and AST was lower than before treatment(t=7.354, P<0.05), but the experiment improvement of liver function indexes of the above groups after treatment was better than that of the control group(t=11.893, 4.885, 8.432, 6.986, P<0.05). The incidence of adverse reactions such as palpitations, itchy skin, eyelid edema, allergic reaction, and skin flushing in the experimental group was3.9% significantly lower than that in the control group29.4%(χ2=7.803, P<0.05). Conclusion Magnesium glycyrrhizinate has a good hepatoprotective effect on chemotherapy patients with malignant tumors, and the incidence of adverse reactions is low, which can be widely applied in clinic.
Objective To observe the liver protection effect of patients with chemotherapy for malignant tumors treated with magnesium isoglycyrrhizinate. Methods 102 patients with chemotherapy for malignant tumor admitted to our hospital from July 2014 to July 2018 were convenient randomly divided into experimental group(51 cases treated with magnesium isoglycyrrhizinate) and control group(51 cases with thiopro tablets treatment), compared with two groups of patients before and after treatment serum alkaline phosphatase(ALP), serum aspartate aminotransferase(AST), serum total bilirubin(TBIL), serum alanine aminotransferase(ALT) changes in indicators and the incidence of adverse reactions. Results The levels of ALP,TBIL and ALT in the two groups were higher than those before treatment(t=13.232, 5.348, 9.764, P<0.05), and AST was lower than before treatment(t=7.354, P<0.05), but the experiment improvement of liver function indexes of the above groups after treatment was better than that of the control group(t=11.893, 4.885, 8.432, 6.986, P<0.05). The incidence of adverse reactions such as palpitations, itchy skin, eyelid edema, allergic reaction, and skin flushing in the experimental group was3.9% significantly lower than that in the control group29.4%(χ2=7.803, P<0.05). Conclusion Magnesium glycyrrhizinate has a good hepatoprotective effect on chemotherapy patients with malignant tumors, and the incidence of adverse reactions is low, which can be widely applied in clinic.
引文
[1]叶建新,黄永健,郑炜,等.异甘草酸镁在胃肠道恶性肿瘤术后辅助化疗时的保肝作用研究[J].实用临床医药杂志,2014,14(2):42-44.
[2]夏俊.异甘草酸镁在化疗后肝功能异常治疗中的临床应用[J].现代中西医结合杂志,2015,21(9):958-959.
[3]邱邦东,陈琴.甘草酸二胺肠溶剂胶囊预防乙肝表面抗原阳性患者抗结核治疗致肝损害的疗效观察[J].中外医学研究,2014,8(17):79.
[4]张宪祥,张炳远,吴力群,等.异甘草酸镁对肝切除术后的保肝作用[J].世界华人消化杂志,2015,18(2):189-194.
[5]杨瑞芹.异甘草酸镁注射液治疗药物性肝病68例[J].医药导报,2014,30(5):618-619.
[6]王宝利,崔建东.异甘草酸镁在妇科恶性肿瘤术后辅助化疗时护肝作用研究[J].现代肿瘤医学,2014,22(8):1939-1940.
[7]李志宏,郝磊,孔佩艳,等.异甘草酸镁治疗化疗药物性肝损害的临床疗效观察[J].实用临床医药杂志,2015,15(1):88-89.
[8]章志学.异甘草酸镁与复方甘草酸单胺治疗血液肿瘤化疗后药物性肝损害的疗效比较[J].实用临床医药杂志,2011,15(13):18-20.
[9]余建国,王晓伟,程滢,等.异甘草酸镁联合舒血宁治疗慢性乙型肝炎疗效观察[J].实用肝脏病杂志,2012,15(1):44-45
[10]黄平,钟艳丹.异甘草酸镁注射液联合硫普罗宁治疗化疗后肝损害临床观察[J].中国医药,2015,7(11):1466-1467.
[11]许炜璐,李明.异甘草酸镁对原发性肝癌肝动脉化疗栓塞术后的保肝作用观察[J].中国医药,2012,7(4):401-402.
[12]熊海林,孙爱华,何樱,等.异甘草酸镁预防大肠癌术后辅助化疗相关性肝损害的临床观察[J].中国医药,2012,7(7):904-905.
[2]夏俊.异甘草酸镁在化疗后肝功能异常治疗中的临床应用[J].现代中西医结合杂志,2015,21(9):958-959.
[3]邱邦东,陈琴.甘草酸二胺肠溶剂胶囊预防乙肝表面抗原阳性患者抗结核治疗致肝损害的疗效观察[J].中外医学研究,2014,8(17):79.
[4]张宪祥,张炳远,吴力群,等.异甘草酸镁对肝切除术后的保肝作用[J].世界华人消化杂志,2015,18(2):189-194.
[5]杨瑞芹.异甘草酸镁注射液治疗药物性肝病68例[J].医药导报,2014,30(5):618-619.
[6]王宝利,崔建东.异甘草酸镁在妇科恶性肿瘤术后辅助化疗时护肝作用研究[J].现代肿瘤医学,2014,22(8):1939-1940.
[7]李志宏,郝磊,孔佩艳,等.异甘草酸镁治疗化疗药物性肝损害的临床疗效观察[J].实用临床医药杂志,2015,15(1):88-89.
[8]章志学.异甘草酸镁与复方甘草酸单胺治疗血液肿瘤化疗后药物性肝损害的疗效比较[J].实用临床医药杂志,2011,15(13):18-20.
[9]余建国,王晓伟,程滢,等.异甘草酸镁联合舒血宁治疗慢性乙型肝炎疗效观察[J].实用肝脏病杂志,2012,15(1):44-45
[10]黄平,钟艳丹.异甘草酸镁注射液联合硫普罗宁治疗化疗后肝损害临床观察[J].中国医药,2015,7(11):1466-1467.
[11]许炜璐,李明.异甘草酸镁对原发性肝癌肝动脉化疗栓塞术后的保肝作用观察[J].中国医药,2012,7(4):401-402.
[12]熊海林,孙爱华,何樱,等.异甘草酸镁预防大肠癌术后辅助化疗相关性肝损害的临床观察[J].中国医药,2012,7(7):904-905.